Reaction

Product Communication Issue reporting signals

Last recalculated 2026-09-14T18:28:35.993900+00:00 · 8,409 reports · 67 co-occurring drugs

As of the last recalculation, Product Communication Issue appears in 8,409 FAERS reports alongside 67 co-occurring drug terms. The strongest observed disproportionality signal is EVOLOCUMAB (PRR 61.0).

Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.

Drug	Co-reports	PRR	ROR
Evolocumab	2,723	61.0	62.0
Erenumab-Aooe	659	32.0	32.4
Oral Semaglutide	752	27.7	28.0
Levodopa	78	16.1	16.2
Somatropin	424	15.0	15.1
Pegfilgrastim	345	9.0	9.0
Trifluridine And Tipiracil	22	5.1	5.1
Fremanezumab-Vfrm	19	4.1	4.1
Insulin Degludec	37	3.9	3.9
Nirmatrelvir And Ritonavir	69	3.2	3.2
Rimegepant Sulfate	15	2.9	2.9
Romosozumab-Aqqg	15	2.7	2.7
Cenobamate	9	2.7	2.7
Fluticasone Furoate, Umeclidinium Bromide And Vilanterol Trifenatate	44	2.6	2.6
Fluticasone Furoate And Vilanterol Trifenatate	38	2.6	2.6
Budesonide, Glycopyrrolate, And Formoterol Fumarate	11	2.6	2.6
Umeclidinium Bromide And Vilanterol Trifenatate	17	2.5	2.5
Carbidopa And Levodopa	46	2.4	2.4
Liraglutide	47	2.4	2.4
Finasteride	55	2.3	2.3
Umeclidinium	8	2.2	2.2
Methimazole	7	2.2	2.2
Insulin Aspart	57	2.1	2.1
Mupirocin	11	2.0	2.0
Rasagiline Mesylate	9	2.0	2.0
Human Insulin	10	2.0	2.0
Mupirocin Calcium	11	2.0	2.0
Fluticasone Furoate	9	1.8	1.8
Cabotegravir	6	1.8	1.8
Misoprostol	7	1.8	1.8
Linaclotide	19	1.8	1.8
Lifitegrast	11	1.7	1.7
Instalax Polyethylene Glycol 3350	8	1.6	1.6
Polyethylene Glycol 400	8	1.6	1.6
Eplerenone	8	1.5	1.5
Dutasteride	5	1.5	1.5
Icosapent Ethyl	5	1.5	1.5
Naltrexone Hydrochloride And Bupropion Hydrochloride	5	1.5	1.5
Dolutegravir Sodium	5	1.4	1.4
Rotigotine	8	1.4	1.4
Empagliflozin	37	1.4	1.4
Belimumab	17	1.3	1.3
Rifaximin	11	1.3	1.3
Entecavir	6	1.3	1.3
Treprostinil	64	1.3	1.3
Guanfacine	4	1.3	1.3
Miconazole Nitrate	4	1.1	1.1
Tobramycin	10	1.0	1.0
Methylphenidate	12	1.0	1.0
Acetaminophen, Aspirin (Nsaid) And Caffeine	7	1.0	1.0
Dronedarone	4	1.0	1.0
Denosumab	79	1.0	1.0
Tirzepatide	63	1.0	1.0
Velpatasvir And Sofosbuvir	5	1.0	1.0
Galcanezumab-Gnlm	12	0.9	0.9
Vibegron	3	0.9	0.9
Etanercept	221	0.9	0.9
Dulaglutide	32	0.9	0.9
Apalutamide	4	0.8	0.8
Acetaminophen, Aspirin, And Caffeine	7	0.8	0.8
Alirocumab	8	0.8	0.8
Buprenorphine	29	0.8	0.8
Ixekizumab	11	0.7	0.7
Bictegravir Sodium, Emtricitabine, And Tenofovir Alafenamide Fumarate	5	0.7	0.7
Glecaprevir And Pibrentasvir	3	0.7	0.7
Abaloparatide	8	0.7	0.7
Guselkumab	7	0.5	0.5

Related reactions

Data source: openFDA FAERS. See the OpenPV methodology and limitations.